# A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

> **NCT03627052** · PHASE2 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03627052
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-20
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns.
- **Last updated:** 2019-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627052, "A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03627052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*